Comparative Effectiveness of Aminoglycosides, Polymyxin B, and Tigecycline for Clearance of Carbapenem-Resistant Klebsiella pneumoniae from Urine
Open Access
- 1 December 2011
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (12) , 5893-5899
Abstract
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an increasingly common cause of health care-associated urinary tract infections. Antimicrobials with in vitro activity against CRKP are typically limited to polymyxins, tigecycline, and often, aminoglycosides. We conducted a retrospective cohort study of cases of CRKP bacteriuria at New York-Presbyterian Hospital from January 2005 through June 2010 to compare microbiologic clearance rates based on the use of polymyxin B, tigecycline, or an aminoglycoside. We constructed three active antimicrobial cohorts based on the active agent used and an untreated cohort of cases that did not receive antimicrobial therapy with Gram-negative activity. Microbiologic clearance was defined as having a follow-up urine culture that did not yield CRKP. Cases without an appropriate follow-up culture or that received multiple active agents or less than 3 days of the active agent were excluded. Eighty-seven cases were included in the active antimicrobial cohorts, and 69 were included in the untreated cohort. The microbiologic clearance rate was 88% in the aminoglycoside cohort ( n = 41), compared to 64% in the polymyxin B ( P = 0.02; n = 25), 43% in the tigecycline ( P < 0.001; n = 21), and 36% in the untreated ( P < 0.001; n = 69) cohorts. Using multivariate analysis, the odds of clearance were lower for the polymyxin B (odds ratio [OR], 0.10; P = 0.003), tigecycline (OR, 0.08; P = 0.001), and untreated (OR, 0.14; P = 0.003) cohorts than for the aminoglycoside cohort. Treatment with an aminoglycoside, when active in vitro , was associated with a significantly higher rate of microbiologic clearance of CRKP bacteriuria than treatment with either polymyxin B or tigecycline.Keywords
This publication has 27 references indexed in Scilit:
- Successful treatment with tigecycline of two patients with complicated urinary tract infections caused by extended-spectrum -lactamase-producing Escherichia coliJournal of Antimicrobial Chemotherapy, 2010
- Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trialsJournal of Antimicrobial Chemotherapy, 2007
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of TigecyclineJournal of Chemotherapy, 2005
- Emergence of KPC-Possessing Klebsiella pneumoniae in Brooklyn, New York: Epidemiology and Recommendations for DetectionAntimicrobial Agents and Chemotherapy, 2005
- Rapid Spread of Carbapenem-Resistant Klebsiella pneumoniae in New York CityArchives of internal medicine (1960), 2005
- Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agentsJournal of Antimicrobial Chemotherapy, 2005
- Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonateJournal of Antimicrobial Chemotherapy, 2004
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- INFLUENCE OF DOSE IN THE URINARY-EXCRETION OF AMIKACIN1984
- Elimination of tritiated gentamicin in normal human subjects and in patients with severely impaired renal functionClinical Pharmacology & Therapeutics, 1973